Illumina to quickly divest Grail if it loses EU or US appeal: report
Maksim Labkouski
Illumina (NASDAQ:ILMN) will reportedly quickly divest itself of cancer test developer Grail if it loses its US or EU appeals case.
EU regulators plan to order Illumina on Thursday to sell Grail, which it acquired for $7.1B in 2021 without first obtaining regulatory approval, Reuters reported on Tuesday, citing a source close to the matter.
Illumina intends to divest Grail as "expeditiously as possible" if it loses its appeals case in the EU or US, Reuters said in a follow-up report on Wednesday.
EU antitrust regulators fined Illumina $475M in July for going through with the takeover without first securing regulatory approval.
The FTC has also ordered Illumina to divest Grail. Illumina has appealed the decision. 

More on Illumina

Illumina, Inc. (ILMN) Morgan Stanley 21st Annual Global Healthcare Conference - (Transcript)
Illumina: Genetic Plot Twist, Time To Unravel The Stock
Illumina, Inc. (ILMN) UBS MedTech, Tools and Genomics Summit 2023 Conference (Transcript)
Illumina falls amid reports of an EU order to sell Grail
Bernstein bullish on Thermo, Revvity, Guardant, PacBio; bearish on Illumina